(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 8% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Ani Pharmaceuticals's revenue in 2024 is $486,816,000.On average, 4 Wall Street analysts forecast ANIP's revenue for 2024 to be $11,238,366,781, with the lowest ANIP revenue forecast at $11,163,430,986, and the highest ANIP revenue forecast at $11,286,110,684. On average, 4 Wall Street analysts forecast ANIP's revenue for 2025 to be $12,137,322,297, with the lowest ANIP revenue forecast at $11,844,493,023, and the highest ANIP revenue forecast at $12,331,206,810.
In 2026, ANIP is forecast to generate $12,897,388,374 in revenue, with the lowest revenue forecast at $12,705,991,181 and the highest revenue forecast at $13,233,387,411.